Phase I Study of Preoperative Chemoradiation With S-1 and Oxaliplatin in Patients With Locally Advanced Resectable Rectal Cancer

Article ID	Journal	Published Year	Pages	File Type
8230563	International Journal of Radiation OncologyBiologyPhysics	2011	6 Pages	PDF

Abstract

The recommended dose of S-1 was determined to be 80 mg/m2/day when combined with oxaliplatin in preoperative CRT, and a Phase II trial is now ongoing.

Keywords

S-1 Oxaliplatin Rectal cancer Preoperative chemoradiotherapy Phase I study

Related Topics

Physical Sciences and Engineering Physics and Astronomy Radiation

Preview

Phase I Study of Preoperative Chemoradiation With S-1 and Oxaliplatin in Patients With Locally Advanced Resectable Rectal Cancer

Authors

Yong Sang M.D., Jae-Lyun M.D., Ph.D., Jin Hong M.D., Jong Hoon M.D., Ph.D., Sang Nam M.D., Seok-Byung M.D., Ph.D., Chang Sik M.D., Ph.D., Mi-Jung M.D., Se-Jin M.D., Ph.D., Jung Shin M.D., Ph.D., Jin Cheon M.D., Ph.D., Tae Won M.D., Ph.D.,